Why Takeda Is Focusing So Much On Plasma-Derived Therapies
By Ben Comer, Chief Editor, Life Science Leader
He has nothing against the U.K., his native country, but Giles Platford, president of Takeda’s plasma-derived therapies (PDT) business unit and a member of the company’s executive leadership team, hasn’t lived there in more than 20 years. Over the last two decades, his experiences working in leadership roles across 10 different countries and a handful of biopharmaceutical companies have imbued him with a distinctive perspective on global health and a keen understanding of the challenges many patients face in gaining reliable access to the medications they need. Additionally, Platford’s globe-trotting taught him the business value of diverse viewpoints, which are reflected in his leadership teams, and the importance of partnerships in solving entrenched problems.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.